Development of immune-specific interaction potentials and their application in the multi-agent-system VaccImm

Area of Science:

• Computational immunology
• Cancer immunotherapy
• Systems biology

Background:

• Peptide vaccination offers a promising personalized approach to cancer therapy, but experimental parameterization is challenging.
• In silico models can aid in understanding complex immune responses and optimizing treatment parameters.
• Existing models often lack specificity for immune receptor-ligand interactions.

Purpose of the Study:

• To develop and validate novel, immune-specific empirical interaction potentials for B-cell and T-cell receptor complexes.
• To integrate these potentials into an agent-based model (VaccImm) for simulating cancer peptide vaccination therapy.
• To analyze the impact of these new potentials on simulating anti-tumor immune responses and identify factors contributing to treatment failure.

Main Methods:

• Development of two empirical interaction potentials tailored for B-cell receptor (BCR) and T-cell receptor (TCR) complexes.
• Validation of these potentials against a general potential.
• Application of potentials within the VaccImm multi-agent system, incorporating amino acid sequence data for receptors and ligands.
• Integration with established methods for predicting major histocompatibility complex (MHC)-binding peptides.

Main Results:

• The newly developed immune-specific interaction potentials were successfully integrated into the VaccImm model.
• The study assessed the influence of different model modules on simulation outcomes and their interdependencies.
• Analysis provided insights into the reasons for potential failures in inducing an immune response during peptide vaccination therapy.

Conclusions:

• The research presents novel immune-specific interaction potentials enhancing the accuracy of in silico simulations for peptide vaccination.
• The VaccImm model, equipped with these potentials, serves as a valuable tool for simulating and optimizing personalized cancer vaccine strategies.
• This work contributes to a systems-level understanding of immune responses in cancer therapy, guiding future treatment development.